Skip to main content

Table 2 Patientsā€™ clinical characteristics after treatment with cTACE and DEB-TACE. (Nā€‰=ā€‰273)

From: Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma

Variables

cTACE (nā€‰=ā€‰201)

DEB-TACE (nā€‰=ā€‰72)

p-value

GOT (IU/L)

156.76ā€‰Ā±ā€‰176.58

73.31ā€‰Ā±ā€‰45.50

<ā€‰0.001

GOT

ā€ƒNot normal

153 (76.1)

46 (63.9)

0.045

ā€ƒNormal

48 (23.9)

26 (36.1)

Ā 

GPT (IU/L)

170.91ā€‰Ā±ā€‰266.13

94.17ā€‰Ā±ā€‰101.44

0.014

GPT

ā€ƒNot normal

139 (69.2)

47 (65.3)

0.545

ā€ƒNormal

62 (30.8)

25 (34.7)

Ā 

Bilirubin (mg/dL)

1.38ā€‰Ā±ā€‰0.99

0.98ā€‰Ā±ā€‰0.57

0.002

Bilirubin

ā€ƒNot normal

75 (37.3)

14 (19.4)

0.006

ā€ƒNormal

126 (62.7)

58 (80.6)

Ā 

Albumin (g/dL)

3.81ā€‰Ā±ā€‰0.43

3.87ā€‰Ā±ā€‰0.42

0.325

Albumin

ā€ƒNot normal

37 (18.4)

12 (16.7)

0.741

ā€ƒNormal

164 (81.6)

60 (83.3)

Ā 

Cholangitis

ā€ƒNo

193 (96)

70 (97.2)

0.641

ā€ƒYes

8 (4)

2 (2.8)

Ā 
  1. Aspartate aminotransferase (GOT), Alanine aminotransferase (GPT)
  2. Data are summarized as meanā€‰Ā±ā€‰SD and n (%) for continuous and categorical variables by treatment. Differences between treatments were compared using Mann-Whitney U test for continuous variables and Chi-square test / or Fisherā€™s exact test for categorical variables
  3. All serious AE were classified as cholangitis, none as biloma
  4. Bold p-values indicate statistical significance (pā€‰<ā€‰0.05)